Bemarituzumab (anti-FGFR2)(Ab170514)-阿拉丁

货号 (SKU)	包装规格	是否现货
Ab170514-100μg	100μg	期货
Ab170514-1mg	1mg	现货
Ab170514-5mg	5mg	现货
Ab170514-10mg	10mg	期货

基本信息

产品名称	Bemarituzumab (anti-FGFR2)
英文别名	EC 2.7.10.1 \| FGFR-2 \| Keratinocyte growth factor receptor \| KGFR \| K-sam
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	FGFR2
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
阳性对照	Lot by Lot
偶联标记	1

产品属性

抗体类型	Primary antibody
克隆	1
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	26.5 kDa (Light Chain) & 50.6 kDa (Heavy Chain), under reducing conditions; 171.4 kDa, under non-reducing conditions.
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	1952272-74-0

数据库链接

IMGT/mAb-DB	770

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

图片

SEC: Bemarituzumab (anti-FGFR2) (Ab170514)

Bemarituzumab (anti-FGFR2) (Ab170514) - SEC
The purity of Bemarituzumab (anti-FGFR2) (Ab170514) is more than 95% verified by HPLC.

ELISA: Bemarituzumab (anti-FGFR2) (Ab170514)

Bemarituzumab (anti-FGFR2) (Ab170514) - ELISA
Immobilized hu-FGFR2-β-IIIb-ECD-His 2 μg/mL can bind Bemarituzumab (anti-FGFR2) (Ab170514) with the EC₅₀ of 13.35 ng/mL.

产品问答

登录提交问题

查看全部

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Xiang H, Liu L, Gao Y, Ahene A, Macal M, Hsu AW, Dreiling L, Collins H. (2020) Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial.. Cancer Chemother Pharmacol, 86 (5): (595-606). [PMID:32965540]
2. Sanford M, McCormack PL. (2020) Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma.. Cancer Discov, 10 (5): (638). [PMID:32220925]
3. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.. (1998) Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.. J Med Chem, 41 (5): (742-751). [PMID:9513602]
4. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433]
5. Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, Mohammadi M. (2007) A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.. Mol Cell, 27 (5): (717-30). [PMID:17803937]
6. Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K, Hasegawa K, Kobayashi Y, Takahashi N, Takahashi K et al.. (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.. J Med Chem, 48 (5): (1359-66). [PMID:15743179]
7. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al.. (2010) A structure-guided approach to creating covalent FGFR inhibitors.. Chem Biol, 17 (3): (285-95). [PMID:20338520]
8. Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA et al.. (2006) Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.. J Med Chem, 49 (4): (1475-85). [PMID:16480284]
9. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099]
10. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.. ACS Med Chem Lett, 4 (1): (91-7). [PMID:24900568]
11. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al.. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.. Cancer Res, 70 (4): (1524-33). [PMID:20145145]
12. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K et al.. (2011) A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.. Mol Cancer Ther, 10 (11): (2200-10). [PMID:21900693]
13. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238]
14. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA et al.. (2002) Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.. J Med Chem, 45 (17): (3772-93). [PMID:12166950]
15. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO et al.. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 42 (26): (5369-89). [PMID:10639280]
16. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N et al.. (2015) First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.. Cancer Discov, 5 (4): (424-37). [PMID:25776529]
17. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
18. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, Ron D, Aaronson SA, Mohammadi M. (2003) Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.. Proc Natl Acad Sci USA, 100 (5): (2266-71). [PMID:12591959]
19. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G. (2016) Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.. PLoS ONE, 11 (9): (e0162594). [PMID:27627808]
20. Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J et al.. (2017) Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.. J Med Chem, 60 (15): (6516-6527). [PMID:28665128]
21. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898]
22. Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W, Cai Z et al.. (2019) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy.. J Med Chem, 62 (14): (6665-6681). [PMID:31095385]
23. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al.. (2013) Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.. J Med Chem, 56 (3): (879-94). [PMID:23301703]
24. Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W et al.. (2016) Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.. Eur J Cancer, 61 (13): (20-8). [PMID:27136102]
25. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.. J Biol Chem, 282 (37): (26687-26695). [PMID:17623664]
26. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong. (2013-04-23) Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.. Journal of medicinal chemistry, 56 ((9)): (3531-3545). [PMID:23600806]
27. Sung Hee Hwang, Aaron T Wecksler, Guodong Zhang, Christophe Morisseau, Long V Nguyen, Samuel H Fu, Bruce D Hammock,. (2013-06-04) Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.. Bioorganic & medicinal chemistry letters, 23 ((13)): ( 3732-3737 ). [PMID:23726028]
28. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.. Bioorg Med Chem Lett, 14 (13): (3601-3605). [PMID:15177483]
29. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.. (2005) Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.. J Med Chem, 48 (12): (3991-4008). [PMID:15943473]
30. Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.. (2005) Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.. J Med Chem, 48 (15): (4892-4909). [PMID:16033269]
31. Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X.. (2005) Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.. J Med Chem, 48 (6): (1886-1900). [PMID:15771433]
32. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.. (2005) Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.. J Med Chem, 48 (7): (2371-2387). [PMID:15801830]
33. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G.. (2006) Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.. Bioorg Med Chem Lett, 16 (2): (262-266). [PMID:16249085]
34. McDermott LA, Higgins B, Simcox M, Luk KC, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Liu JJ, Konzelmann F, Zhang Z, Flynn T, Morales O, Chen Y.. (2006) Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.. Bioorg Med Chem Lett, 16 (7): (1950-1953). [PMID:16460940]
35. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H.. (2007) Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.. J Med Chem, 50 (18): (4351-4373). [PMID:17696416]
36. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425]
37. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.. (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors.. J Med Chem, 51 (18): (5766-5779). [PMID:18763753]
38. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS.. (2009) Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.. J Med Chem, 52 (21): (6880-6888). [PMID:19888761]
39. Kim H, Kim M, Lee J, Yu H, Hah JM.. (2011) Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.. Bioorg Med Chem, 19 (22): (6760-6767). [PMID:22014755]
40. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.. J Med Chem, 55 (9): (4407-4424). [PMID:22533818]
41. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B.. (2012) Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.. Bioorg Med Chem Lett, 22 (24): (7634-7640). [PMID:23107479]
42. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY.. (2013) Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.. J Med Chem, 56 (4): (1641-1655). [PMID:23362959]
43. Kusakabe K, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai H, Nakamura Y.. (2013) Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).. J Med Chem, 56 (11): (4343-4356). [PMID:23634759]
44. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA.. (2015) Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.. J Med Chem, 58 (1): (443-456). [PMID:25475894]
45. Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.. (2015) Nintedanib: from discovery to the clinic.. J Med Chem, 58 (3): (1053-1063). [PMID:25474320]
46. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY.. (2015) Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.. Bioorg Med Chem Lett, 25 (20): (4534-4538). [PMID:26342867]
47. Fan J, Dai Y, Shao J, Peng X, Wang C, Cao S, Zhao B, Ai J, Geng M, Duan W.. (2016) Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.. Bioorg Med Chem Lett, 26 (11): (2594-2599). [PMID:27117427]
48. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810]
49. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800]
50. Fu J, Xia A, Qi X.. (2016) Identification of novel peptoid agonists of fibroblast growth factor receptor using microarray-based screening.. Medchemcomm, 7 (6): (1183-1189). [PMID:27721968]
51. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692]
52. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.. (2018) Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.. J Med Chem, 61 (1): (140-157). [PMID:29189002]
53. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471]
54. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448]
55. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (): (1300-1325). [PMID:30195240]
56. Baska F, Sipos A, Őrfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, Cserepes MT, Tóvári J, Garamvölgyi R, Krekó M, Őrfi L.. (2019) Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.. Eur J Med Chem, 184 (): (111710-111710). [PMID:31614258]
57. Wang L, Zhang Y, Zhang Q, Zhu G, Zhang Z, Duan C, Lu T, Tang W.. (2019) Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.. Eur J Med Chem, 163 (): (243-255). [PMID:30529543]
58. Lin X, Yosaatmadja Y, Kalyukina M, Middleditch MJ, Zhang Z, Lu X, Ding K, Patterson AV, Smaill JB, Squire CJ.. (2019) Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.. ACS Med Chem Lett, 10 (8): (1180-1186). [PMID:31413803]
59. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671]
60. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P.. (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.. Eur J Med Chem, 175 (): (309-329). [PMID:31096153]
61. Lu X, Chen H, Patterson AV, Smaill JB, Ding K.. (2019) Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.. J Med Chem, 62 (6): (2905-2915). [PMID:30403487]
62. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (): (671-689). [PMID:30572178]
63. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE.. (2020) Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.. ACS Med Chem Lett, 11 (4): (558-565). [PMID:32292564]
64. Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M.. (2020) Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.. Bioorg Med Chem, 28 (10): (115453-115453). [PMID:32278710]
65. Rezende Miranda R,Fu Y,Chen X,Perino J,Cao P,Carpten J,Chen Y,Zhang C. (2020) Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.. J Med Chem, 63 (20): (11484-11497). [PMID:33030342]
66. Yan G,Zhong X,Pu C,Yue L,Shan H,Lan S,Zhou M,Hou X,Yang J,Li D,Fan S,Li R. (2021) Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design.. J Med Chem, 64 (3.0): (1558-1569). [PMID:33471528]
67. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P. (2020) Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.. J Med Chem, 63 (21.0): (12542-12573). [PMID:32930584]
68. Kuriwaki I,Kameda M,Iikubo K,Hisamichi H,Kawamoto Y,Kikuchi S,Moritomo H,Kondoh Y,Terasaka T,Amano Y,Tateishi Y,Echizen Y,Iwai Y,Noda A,Tomiyama H,Nakazawa T,Hirano M. (2021) Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.. Bioorg Med Chem, 33 (): (116019-116019). [PMID:33486159]
69. Liu H,Niu D,Tham Sjin RT,Dubrovskiy A,Zhu Z,McDonald JJ,Fahnoe K,Wang Z,Munson M,Scholte A,Barrague M,Fitzgerald M,Liu J,Kothe M,Sun F,Murtie J,Ge J,Rocnik J,Harvey D,Ospina B,Perron K,Zheng G,Shehu E,D'Agostino LA. (2020) Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma.. ACS Med Chem Lett, 11 (10): (1899-1904). [PMID:33062171]
70. Chen X,Liu Y,Zhang L,Chen D,Dong Z,Zhao C,Liu Z,Xia Q,Wu J,Chen Y,Zheng X,Cai Y. (2021) Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.. Eur J Med Chem, 214 (): (113219-113219). [PMID:33618175]
71. Miki, T T and 6 more authors.. (1992) Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.. Proceedings of the National Academy of Sciences of the United States of America, (1): (). [PMID:1309608]
72. Dell, K R KR and Williams, L T LT.. (1992) A novel form of fibroblast growth factor receptor 2. Alternative splicing of the third immunoglobulin-like domain confers ligand binding specificity.. The Journal of biological chemistry, (15): (). [PMID:1400433]
73. Seno, M M, Sasada, R R, Watanabe, T T, Ishimaru, K K and Igarashi, K K.. (1991) Two cDNAs encoding novel human FGF receptor.. Biochimica et biophysica acta, (13): (). [PMID:1647213]
74. Dionne, C A CA and 8 more authors.. (1990) Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.. The EMBO journal, (): (). [PMID:1697263]
75. Houssaint, E E and 6 more authors.. (1990) Related fibroblast growth factor receptor genes exist in the human genome.. Proceedings of the National Academy of Sciences of the United States of America, (): (). [PMID:2172978]
76. Hattori, Y Y and 9 more authors.. (1990) K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes.. Proceedings of the National Academy of Sciences of the United States of America, (): (). [PMID:2377625]
77. Gorry, M C MC and 9 more authors.. (1995) Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome.. Human molecular genetics, (): (). [PMID:7581378]
78. Oldridge, M M and 9 more authors.. (1995) Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome.. Human molecular genetics, (): (). [PMID:7655462]
79. Park, W J WJ and 7 more authors.. (1995) Analysis of phenotypic features and FGFR2 mutations in Apert syndrome.. American journal of human genetics, (): (). [PMID:7668257]
80. Lajeunie, E E and 5 more authors.. (1995) FGFR2 mutations in Pfeiffer syndrome.. Nature genetics, (): (). [PMID:7719333]
81. Wilkie, A O AO and 9 more authors.. (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.. Nature genetics, (): (). [PMID:7719344]
82. Rutland, P P and 9 more authors.. (1995) Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes.. Nature genetics, (): (). [PMID:7719345]
83. Wilson, S E SE and 5 more authors.. (1994) Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and their receptors in human breast cells and tissues: alternative receptors.. Cellular & molecular biology research, (): (). [PMID:7866434]
84. Jabs, E W EW and 9 more authors.. (1994) Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2.. Nature genetics, (): (). [PMID:7874170]
85. Reardon, W W and 5 more authors.. (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome.. Nature genetics, (): (). [PMID:7987400]
86. Park, W J WJ and 7 more authors.. (1995) Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability.. Human molecular genetics, (): (). [PMID:8528214]
87. Meyers, G A GA and 11 more authors.. (1996) FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing.. American journal of human genetics, (): (). [PMID:8644708]
88. Moloney, D M DM and 6 more authors.. (1996) Exclusive paternal origin of new mutations in Apert syndrome.. Nature genetics, (): (). [PMID:8673103]
89. Wada, C C and 7 more authors.. (1996) [Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth factor receptor 2 and rapid mutational analysis in Apert syndrome].. Rinsho byori. The Japanese journal of clinical pathology, (): (). [PMID:8676562]
90. Przylepa, K A KA and 11 more authors.. (1996) Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome.. Nature genetics, (): (). [PMID:8696350]
91. Steinberger, D D, Mulliken, J B JB and Müller, U U.. (1996) Crouzon syndrome: previously unrecognized deletion, duplication, and point mutation within FGFR2 gene.. Human mutation, (): (). [PMID:8956050]
92. Oldridge, M M and 12 more authors.. (1997) Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2.. Human molecular genetics, (): (). [PMID:9002682]
93. Tartaglia, M M, Valeri, S S, Velardi, F F, Di Rocco, C C and Battaglia, P A PA.. (1997) Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome.. Human genetics, (): (). [PMID:9150725]
94. Steinberger, D D, Collmann, H H, Schmalenberger, B B and Müller, U U.. (1997) A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with Crouzon phenotype and plagiocephaly.. Journal of medical genetics, (): (). [PMID:9152842]
95. Tartaglia, M M and 5 more authors.. (1997) Jackson-Weiss syndrome: identification of two novel FGFR2 missense mutations shared with Crouzon and Pfeiffer craniosynostotic disorders.. Human genetics, (): (). [PMID:9385368]
96. Tsai, F J FJ and 5 more authors.. (1998) Two common mutations 934C to G and 937C to G of fibroblast growth factor receptor 2 (FGFR2) gene in Chinese patients with Apert syndrome.. Human mutation, (): (). [PMID:9452027]
97. Steinberger, D D, Vriend, G G, Mulliken, J B JB and Müller, U U.. (1998) The mutations in FGFR2-associated craniosynostoses are clustered in five structural elements of immunoglobulin-like domain III of the receptor.. Human genetics, (): (). [PMID:9521581]
98. Paznekas, W A WA and 12 more authors.. (1998) Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR mutations.. American journal of human genetics, (): (). [PMID:9585583]
99. Passos-Bueno, M R MR and 7 more authors.. (1998) Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.. American journal of medical genetics, (7): (). [PMID:9677057]
100. Mathijssen, I M IM, Vaandrager, J M JM, Hoogeboom, A J AJ, Hesseling-Janssen, A L AL and van den Ouweland, A M AM.. (1998) Pfeiffer's syndrome resulting from an S351C mutation in the fibroblast growth factor receptor-2 gene.. The Journal of craniofacial surgery, (): (). [PMID:9693549]
101. Passos-Bueno, M R MR, Richieri-Costa, A A, Sertié, A L AL and Kneppers, A A.. (1998) Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly.. Journal of medical genetics, (): (). [PMID:9719378]
102. Zhang, Y Y, Gorry, M C MC, Post, J C JC and Ehrlich, G D GD.. (1999) Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family.. Gene, (1): (). [PMID:10196476]
103. Cornejo-Roldan, L R LR, Roessler, E E and Muenke, M M.. (1999) Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome.. Human genetics, (): (). [PMID:10394936]
104. Everett, E T ET, Britto, D A DA, Ward, R E RE and Hartsfield, J K JK.. (1999) A novel FGFR2 gene mutation in Crouzon syndrome associated with apparent nonpenetrance.. The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association, (): (). [PMID:10574673]
105. Stauber, D J DJ, DiGabriele, A D AD and Hendrickson, W A WA.. (2000) Structural interactions of fibroblast growth factor receptor with its ligands.. Proceedings of the National Academy of Sciences of the United States of America, (4): (). [PMID:10618369]
106. Ueda, T T and 10 more authors.. (1999) Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs.. Cancer research, (15): (). [PMID:10626794]
107. Reardon, W W and 16 more authors.. (2000) Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?. Journal of medical genetics, (): (). [PMID:10633130]
108. Glaser, R L RL and 11 more authors.. (2000) Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome and Pfeiffer syndrome.. American journal of human genetics, (): (). [PMID:10712195]
109. Plotnikov, A N AN, Hubbard, S R SR, Schlessinger, J J and Mohammadi, M M.. (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.. Cell, (12): (). [PMID:10830168]
110. Priolo, M M and 7 more authors.. (2000) Pfeiffer syndrome type 2 associated with a single amino acid deletion in the FGFR2 gene.. Clinical genetics, (): (). [PMID:10945669]
111. Johnson, D D, Wall, S A SA, Mann, S S and Wilkie, A O AO.. (2000) A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction leading to craniosynostosis?. European journal of human genetics : EJHG, (): (). [PMID:10951518]
112. Pellegrini, L L, Burke, D F DF, von Delft, F F, Mulloy, B B and Blundell, T L TL.. (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin.. Nature, (26): (). [PMID:11069186]
113. Kress, W W, Collmann, H H, Büsse, M M, Halliger-Keller, B B and Mueller, C R CR.. (2000) Clustering of FGFR2 gene mutations inpatients with Pfeiffer and Crouzon syndromes (FGFR2-associated craniosynostoses).. Cytogenetics and cell genetics, (): (). [PMID:11173845]
114. Tsai, F J FJ, Yang, C F CF, Wu, J Y JY, Tsai, C H CH and Lee, C C CC.. (2001) Mutation analysis of Crouzon syndrome and identification of one novel mutation in Taiwanese patients.. Pediatrics international : official journal of the Japan Pediatric Society, (): (). [PMID:11380921]
115. Ibrahimi, O A OA and 5 more authors.. (2001) Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.. Proceedings of the National Academy of Sciences of the United States of America, (19): (). [PMID:11390973]
116. Kan, Shih-hsin SH and 14 more authors.. (2002) Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.. American journal of human genetics, (): (). [PMID:11781872]
117. Ingersoll, R G RG and 5 more authors.. (2001) Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and variations.. Cytogenetics and cell genetics, (): (). [PMID:11856867]
118. Wang, T-J TJ and 5 more authors.. (2002) Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson cutis gyrata syndrome.. Clinical genetics, (): (). [PMID:12000365]
119. Lu, Yunbiao Y, Pan, Zhong-Zong ZZ, Devaux, Yvan Y and Ray, Prabir P.. (2003) p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte growth factor receptor and participates in keratinocyte growth factor-mediated inhibition of oxidant-induced cell death.. The Journal of biological chemistry, (21): (). [PMID:12529371]
120. Deloukas, P P and 135 more authors.. (2004) The DNA sequence and comparative analysis of human chromosome 10.. Nature, (27): (). [PMID:15164054]
121. Kaabeche, Karim K, Lemonnier, Jérome J, Le Mée, Sandrine S, Caverzasio, Joseph J and Marie, Pierre J PJ.. (2004) Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.. The Journal of biological chemistry, (27): (). [PMID:15190072]
122. Ceridono, Mara M, Belleudi, Francesca F, Ceccarelli, Simona S and Torrisi, Maria Rosaria MR.. (2005) Tyrosine 769 of the keratinocyte growth factor receptor is required for receptor signaling but not endocytosis.. Biochemical and biophysical research communications, (11): (). [PMID:15629145]
123. Eswarakumar, V P VP, Lax, I I and Schlessinger, J J.. (2005) Cellular signaling by fibroblast growth factor receptors.. Cytokine & growth factor reviews, (): (). [PMID:15863030]
124. McGillivray, G G and 9 more authors.. (2005) Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 tyrosine kinase domain.. Journal of medical genetics, (): (). [PMID:16061565]
125. Robinson, Christopher J CJ, Harmer, Nicholas J NJ, Goodger, Sarah J SJ, Blundell, Tom L TL and Gallagher, John T JT.. (2005) Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes.. The Journal of biological chemistry, (23): (). [PMID:16219767]
126. Olsen, Shaun K SK and 9 more authors.. (2006) Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain.. Genes & development, (15): (). [PMID:16384934]
127. Radtke, Michelle L ML and Kolesar, Jill M JM.. (2005) Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, (): (). [PMID:16390600]
128. Rohmann, Edyta E and 21 more authors.. (2006) Mutations in different components of FGF signaling in LADD syndrome.. Nature genetics, (): (). [PMID:16501574]
129. Zhang, Xiuqin X and 5 more authors.. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.. The Journal of biological chemistry, (9): (). [PMID:16597617]
130. Hatch, Nan E NE, Hudson, Mark M, Seto, Marianne L ML, Cunningham, Michael L ML and Bothwell, Mark M.. (2006) Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.. The Journal of biological chemistry, (15): (). [PMID:16844695]
131. Huang, Yi-Wen YW and 6 more authors.. (2006) Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells.. The Journal of steroid biochemistry and molecular biology, (): (). [PMID:16854582]
132. Zhu, Xuegong X, Lee, Katie K, Asa, Sylvia L SL and Ezzat, Shereen S.. (2007) Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.. The American journal of pathology, (): (). [PMID:17456767]
133. Beaven, Anne W AW and Shea, Thomas C TC.. (2007) Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.. Drugs of today (Barcelona, Spain : 1998), (): (). [PMID:17728847]
134. Matsui, Junji J and 7 more authors.. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.. International journal of cancer, (1): (). [PMID:17943726]
135. Lew, Erin D ED, Bae, Jae Hyun JH, Rohmann, Edyta E, Wollnik, Bernd B and Schlessinger, Joseph J.. (2007) Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.. Proceedings of the National Academy of Sciences of the United States of America, (11): (). [PMID:18056630]
136. Dufour, Cécilie C and 5 more authors.. (2008) FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival.. Bone, (): (). [PMID:18374639]
137. Chen, Huaibin H and 9 more authors.. (2008) A crystallographic snapshot of tyrosine trans-phosphorylation in action.. Proceedings of the National Academy of Sciences of the United States of America, (16): (). [PMID:19060208]
138. Cha, Jiyoung Y JY, Maddileti, Savitri S, Mitin, Natalia N, Harden, T Kendall TK and Der, Channing J CJ.. (2009) Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.. The Journal of biological chemistry, (6): (). [PMID:19103595]
139. and Katoh, Masaru M.. (2009) FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies.. The Journal of investigative dermatology, (): (). [PMID:19387476]
140. Eichholz, Andrew; Merchant, Shairoz and Gaya, Andrew M.. (2010) Anti-angiogenesis therapies: their potential in cancer management.. OncoTargets and therapy, (24): (). [PMID:20616958]
141. Sévère, Nicolas N, Miraoui, Hichem H and Marie, Pierre J PJ.. (2011) The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination.. The Journal of biological chemistry, (8): (). [PMID:21596750]
142. Merrill, Amy E AE and 13 more authors.. (2012) Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling.. American journal of human genetics, (9): (). [PMID:22387015]
143. Gozgit, Joseph M JM and 9 more authors.. (2013) Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.. Cancer chemotherapy and pharmacology, (): (). [PMID:23468082]
144. Tabernero, Josep J and 18 more authors.. (2015) Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (20): (). [PMID:26324363]
145. Perles, Zeev Z and 8 more authors.. (2015) A human laterality disorder caused by a homozygous deleterious mutation in MMP21.. Journal of medical genetics, (): (). [PMID:26429889]
146. Katoh, M M and 7 more authors.. (1992) K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase.. Proceedings of the National Academy of Sciences of the United States of America, (1): (). [PMID:1313574]
147. Pulleyn, L J LJ and 11 more authors.. (1996) Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus.. European journal of human genetics : EJHG, (): (). [PMID:8946174]
148. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): (). [PMID:11752352]

Bemarituzumab (anti-FGFR2)

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

数据库链接

质检证书(COA)

质检报告(COA)

图片

相关文档

质检报告COA

相关技术文章

产品问答

产品问答

参考文献